Relationships between the amyloid precursor protein and its various proteolytic fragments and neuronal systems

Alzheimer's Research and Therapy

Volumn 4, Issue 2, 2012, Pages

  Hunter, Sally ^a   Brayne, Carol ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; BINDING AFFINITY; COGNITIVE DEFECT; DISEASE COURSE; ENDOCYTOSIS; EXTRACELLULAR MATRIX; HUMAN; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; REVIEW;

EID: 84859196011     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt108     Document Type: Review

References (173)

1. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L, Neurology 1991 41 479 486 2011243
2. Neuropathological stageing of Alzheimer-related changes. Braak H, Braak E, Acta Neuropathol 1991 82 239 259 10.1007/BF00308809 1759558
3. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Braak H, Braak E, Neurobiol Aging 1997 18 4 Suppl 85 88 9330992
4. Clinical features of sporadic and familial Alzheimer's disease. Rossor MN, Fox NC, Freeborough PA, Harvey RJ, Neurodegeneration 1996 5 393 397 10.1006/neur.1996.0052 9117552 (Pubitemid 27077899)
5. Alzheimer's disease: genes, proteins, and therapy. Selkoe DJ, Physiol Rev 2001 81 741 766 11274343 (Pubitemid 32267077)
6. Genetic aspects of Alzheimer's disease. Zekanowski C, Religa D, Graff C, Filipek S, Kunicki J, Acta Neurobiol Exp (Wars) 2004 64 19 31 15190677 (Pubitemid 38453803)
7. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Neuropathology Group. Medical Research Council Cognitive Function and Aging Study, Lancet 2001 357 169 75 11213093
8. Age, neuropathology, and dementia. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, Medical Research Council Cognitive Function and Ageing Study, N Engl J Med 2009 360 2302 2309 10.1056/NEJMoa0806142 19474427
9. Neuropathological evaluation of mixed dementia. Jellinger KA, Attems J, J Neurol Sci 2007 257 80 87 10.1016/j.jns.2007.01.045 17324442 (Pubitemid 46856518)
10. Alzheimer's disease: the amyloid cascade hypothesis. Hardy JA, Higgins GA, Science 1992 256 184 185 10.1126/science.1566067 1566067
11. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 353 356 10.1126/science.1072994 12130773 (Pubitemid 34790756)
12. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. Selkoe DJ, J Alzheimers Dis 2001 3 75 80 12214075
13. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Shen J, Kelleher RJ, Proc Natl Acad Sci USA 2007 104 403 409 10.1073/pnas.0608332104 17197420 (Pubitemid 46123039)
14. Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. Koudinov AR, Koudinova NV, J Neurol Sci 2005 229-230 233 240 15760645 (Pubitemid 40341588)
15. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schüssel K, Müller WE, Biochem Pharmacol 2003 66 1627 1634 10.1016/S0006-2952(03)00534-3 14555243 (Pubitemid 38373355)
16. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. Hoyer S, J Neural Transm 2002 109 991 1002 10.1007/s007020200082 12111436 (Pubitemid 34762337)
17. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Hoyer S, Adv Exp Med Biol 2004 541 135 152 10.1007/978-1-4419-8969-7-8 14977212 (Pubitemid 38037371)
18. The cholinergic hypothesis of geriatric memory dysfunction. Bartus RT, Dean RL, Beer B, Lippa AS, Science 1982 217 408 414 10.1126/science.7046051 7046051
19. Calcium and neurodegeneration. Mattson MP, Aging Cell 2007 6 337 350 10.1111/j.1474-9726.2007.00275.x 17328689 (Pubitemid 46785139)
20. Calcium dysregulation in Alzheimer's disease. Bojarski L, Herms J, Kuznicki J, Neurochem Int 2008 52 621 633 10.1016/j.neuint.2007.10.002 18035450
21. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Arendt T, Prog Neurobiol 2003 71 83 248 10.1016/j.pneurobio.2003.09.007 14687983 (Pubitemid 38004483)
22. Changing perspectives regarding late-life dementia. Fotuhi M, Hachinski V, Whitehouse PJ, Nat Rev Neurol 2009 5 649 658 10.1038/nrneurol.2009.175 19918254
23. Research and Alzheimer's disease: an epidemiological perspective. Brayne C, Psychol Med 1993 23 287 296 10.1017/S003329170002835X 8332643 (Pubitemid 23209221)
24. Vulnerabilities in the tau network and the role of ultrasensitive points in tau pathophysiology. Yuraszeck TM, Neveu P, Rodriguez-Fernandez M, Robinson A, Kosik KS, Doyle FJ, PLoS Comput Biol 2010 6 1000997 10.1371/journal.pcbi. 1000997 21085645
25. A domain level interaction network of amyloid precursor protein and Abeta of Alzheimer's disease. Perreau VM, Orchard S, Adlard PA, Bellingham SA, Cappai R, Ciccotosto GD, Cowie TF, Crouch PJ, Duce JA, Evin G, Faux NG, Hill AF, Hung YH, James SA, Li QX, Mok SS, Tew DJ, White AR, Bush AI, Hermjakob H, Masters CL, Proteomics 2010 10 2377 2395 10.1002/pmic.200900773 20391539
26. Perspectives of a systems biology of the synapse: how to transform an indefinite data space into a model? Mewes HW, Wachinger B, Stumpflen V, Pharmacopsychiatry 2010 43 Suppl 1 2 8 20480444
27. Identifying dysfunctional crosstalk of pathways in various regions of Alzheimer's disease brains. Liu ZP, Wang Y, Zhang XS, Chen L, BMC Syst Biol 2010 4 Suppl 2 11 10.1186/1752-0509-4-S2-S11 20840725
28. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Kell DB, Arch Toxicol 2010 84 825 889 10.1007/s00204-010-0577-x 20967426
29. Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Noorbakhsh F, Overall CM, Power C, Trends Neurosci 2009 32 88 100 10.1016/j.tins.2008.10.003 19135729
30. A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. Miller JA, Oldham MC, Geschwind DH, J Neurosci 2008 28 1410 1420 10.1523/JNEUROSCI.4098-07.2008 18256261 (Pubitemid 351231536)
31. Variations in the transcriptome of Alzheimer's disease reveal molecular networks involved in cardiovascular diseases. Ray M, Ruan J, Zhang W, Genome Biol 2008 9 148 10.1186/gb-2008-9-10-r148 18842138
32. Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways. Miller JA, Horvath S, Geschwind DH, Proc Natl Acad Sci USA 2010 107 12698 12703 10.1073/pnas.0914257107 20616000
33. Interactome mapping suggests new mechanistic details underlying Alzheimer's disease. Soler-López M, Zanzoni A, Lluís R, Stelzl U, Aloy P, Genome Res 2011 21 364 376 10.1101/gr.114280.110 21163940
34. UNIPROTKB. http://www.uniprot.org/
35. NCBI Entrez Gene. http://www.ncbi.nlm.nih.gov/gene
36. IntAct. http://ebi.ac.uk/intact/site/
37. Pubmed. http://www.ncbi.nlm.nih.gov/pubmed/
38. Compendium. http://compendium.open.ac.uk/
39. Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and beta-amyloid1-42. Lee DH, Wang HY, J Neurobiol 2003 55 25 30 10.1002/neu.10203 12605456 (Pubitemid 36396959)
40. The inhibitory and facilitatory actions of amyloid-beta peptides on nicotinic ACh receptors and AMPA receptors. Tozaki H, Matsumoto A, Kanno T, Nagai K, Nagata T, Yamamoto S, Nishizaki T, Biochem Biophys Res Commun 2002 294 42 45 10.1016/S0006-291X(02)00429-1 12054737 (Pubitemid 34687211)
41. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. Wang R, Sweeney D, Gandy SE, Sisodia SS, J Biol Chem 1996 271 31894 31902 10.1074/jbc.271.50.31894 8943233 (Pubitemid 26422211)
42. The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zincmodulated heparin-binding superfamily. Bush AI, Pettingell WH Jr, de Paradis M, Tanzi RE, Wasco W, J Biol Chem 1994 269 26618 26621 7929392
43. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Turner PR, O'Connor K, Tate WP, Abraham WC, Prog Neurobiol 2003 70 1 32 10.1016/S0301-0082(03)00089-3 12927332 (Pubitemid 36966639)
44. Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, Chen X, Stokin GB, Koo EH, J Biol Chem 1999 274 18851 18856 10.1074/jbc.274.27.18851 10383380 (Pubitemid 29314074)
45. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH, EMBO J 2002 21 5691 5700 10.1093/emboj/cdf568 12411487 (Pubitemid 35315269)
46. Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. Koo EH, Squazzo SL, Selkoe DJ, Koo CH, J Cell Sci 1996 109 991 998 8743946
47. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, Greenberg BD, Siman R, Scott RW, J Neurosci 1998 18 1743 1752 9464999 (Pubitemid 28103082)
48. Post-translational processing and turnover kinetics of presynaptically targeted amyloid precursor superfamily proteins in the central nervous system. Lyckman AW, Confaloni AM, Thinakaran G, Sisodia SS, Moya KL, J Biol Chem 1998 273 11100 11106 10.1074/jbc.273.18.11100 9556595 (Pubitemid 28204956)
49. In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the beta-amyloid depositing mice. Morales-Corraliza J, Mazzella MJ, Berger JD, Diaz NS, Choi JH, Levy E, Matsuoka Y, Planel E, Mathews PM, PLoS ONE 2009 4 7134 10.1371/journal.pone.0007134 19771166
50. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Selkoe DJ, Annu Rev Cell Biol 1994 10 373 403 10.1146/annurev.cb.10.110194.002105 7888181 (Pubitemid 24372824)
51. APP processing in Alzheimer's disease. Zhang YW, Thompson R, Zhang H, Xu H, Mol Brain 2011 4 3 10.1186/1756-6606-4-3 21214928
52. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. Sun X, He G, Song W, FASEB J 2006 20 1369 1376 10.1096/fj.05-5632com 16816112 (Pubitemid 44943845)
53. Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I. Beher D, Hesse L, Masters CL, Multhaup G, J Biol Chem 1996 271 1613 1620 10.1074/jbc.271.3.1613 8576160 (Pubitemid 26028652)
54. APP-collagen interaction is mediated by a heparin bridge mechanism. Breen KC, Mol Chem Neuropathol 1992 16 109 121 10.1007/BF03159964 1520400
55. DAB1 and Reelin effects on amyloid precursor protein and ApoE receptor 2 trafficking and processing. Hoe HS, Tran TS, Matsuoka Y, Howell BW, Rebeck GW, J Biol Chem 2006 281 35176 35185 10.1074/jbc.M602162200 16951405 (Pubitemid 46036557)
56. Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. Hoe HS, Lee KJ, Carney RS, Lee J, Markova A, Lee JY, Howell BW, Hyman BT, Pak DT, Bu G, Rebeck GW, J Neurosci 2009 29 7459 7473 10.1523/JNEUROSCI. 4872-08.2009 19515914
57. Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts. Gralle M, Ferreira ST, Prog Neurobiol 2007 82 11 32 10.1016/j.pneurobio.2007.02.001 17428603 (Pubitemid 46719589)
58. MatrixDB, the extracellular matrix interaction database. Chautard E, Fatoux-Ardore M, Ballut L, Thierry-Mieg N, Ricard-Blum S, Nucleic Acids Res 2011 39 Database issue 235 240 20852260
59. Structure and biochemical analysis of the heparin-induced E1 dimer of the amyloid precursor protein. Dahms SO, Hoefgen S, Roeser D, Schlott B, Gührs KH, Than ME, Proc Natl Acad Sci USA 2010 107 5381 5386 10.1073/pnas.0911326107 20212142
60. Solution conformation and heparin-induced dimerization of the full-length extracellular domain of the human amyloid precursor protein. Gralle M, Oliveira CL, Guerreiro LH, McKinstry WJ, Galatis D, Masters CL, Cappai R, Parker MW, Ramos CH, Torriani I, Ferreira ST, J Mol Biol 2006 357 493 508 10.1016/j.jmb.2005.12.053 16436282 (Pubitemid 43290750)
61. Amyloid precursor protein and BACE function as oligomers. Multhaup G, Neurodegener Dis 2006 3 270 274 10.1159/000095266 17047367 (Pubitemid 44600314)
62. Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. Gralle M, Botelho MG, Wouters FS, J Biol Chem 2009 284 15016 15025 10.1074/jbc.M808755200 19336403
63. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, Fox M, Mattson MP, J Neurochem 1996 67 1882 1896 8863493 (Pubitemid 26349661)
64. sAPPalpha antagonizes dendritic degeneration and neuron death triggered by proteasomal stress. Copanaki E, Chang S, Vlachos A, Tschäpe JA, Müller UC, Kögel D, Deller T, Mol Cell Neurosci 2010 44 386 393 10.1016/j.mcn.2010.04.007 20472066
65. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E, Neurosci Lett 2000 278 169 172 10.1016/S0304-3940(99)00929-5 10653020 (Pubitemid 30009484)
66. Abeta(1-40) prevents heparanasecatalyzed degradation of heparan sulfate glycosaminoglycans and proteoglycans in vitro. A role for heparan sulfate proteoglycan turnover in Alzheimer's disease. Bame KJ, Danda J, Hassall A, Tumova S, J Biol Chem 1997 272 17005 17011 10.1074/jbc.272.27.17005 9202014 (Pubitemid 27289805)
67. Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases. Klajnert B, Cortijo-Arellano M, Bryszewska M, Cladera J, Biochem Biophys Res Commun 2006 339 577 582 10.1016/j.bbrc.2005.11.053 16310169 (Pubitemid 41739706)
68. Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro. Bergamaschini L, Donarini C, Rossi E, De Luigi A, Vergani C, De Simoni MG, Neurobiol Aging 2002 23 531 536 10.1016/S0197-4580(02)00003-9 12009502 (Pubitemid 34495463)
69. Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. Winkler K, Scharnagl H, Tisljar U, Hoschützky H, Friedrich I, Hoffmann MM, Hüttinger M, Wieland H, März W, J Lipid Res 1999 40 447 455 10064733 (Pubitemid 29116148)
70. Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme. Beckman M, Holsinger RM, Small DH, Biochemistry 2006 45 6703 6714 10.1021/bi052498t 16716081 (Pubitemid 43825371)
71. Diverse fibrillar peptides directly bind the Alzheimer's amyloid precursor protein and amyloid precursor-like protein 2 resulting in cellular accumulation. White AR, Maher F, Brazier MW, Jobling MF, Thyer J, Stewart LR, Thompson A, Gibson R, Masters CL, Multhaup G, Beyreuther K, Barrow CJ, Collins SJ, Cappai R, Brain Res 2003 966 231 244 10.1016/S0006-8993(02)04173-2 12618346 (Pubitemid 36255586)
72. Abeta(1-40)-induced secretion of matrix metalloproteinase-9 results in sAPPalpha release by association with cell surface APP. Talamagas AA, Efthimiopoulos S, Tsilibary EC, Figueiredo-Pereira ME, Tzinia AK, Neurobiol Dis 2007 28 304 315 10.1016/j.nbd.2007.07.016 17761425 (Pubitemid 350123595)
73. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M, Proc Natl Acad Sci USA 2002 99 13217 13221 10.1073/pnas.172504199 12244210
74. Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor. Ling X, Martins RN, Racchi M, Craft S, Helmerhorst E, J Alzheimers Dis 2002 4 369 374 12446969 (Pubitemid 35397803)
75. Muscarine enhances soluble amyloid precursor protein secretion in human neuroblastoma SH-SY5Y by a pathway dependent on protein kinase C(alpha), src-tyrosine kinase and extracellular signal-regulated kinase but not phospholipase C. Canet-Aviles RM, Anderton M, Hooper NM, Turner AJ, Vaughan PF, Brain Res Mol Brain Res 2002 102 62 72 12191495 (Pubitemid 34607743)
76. Abeta hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures. Henriques AG, Vieira SI, da Cruz e Silva EF, da Cruz e Silva OA, J Mol Neurosci 2009 39 248 255 10.1007/s12031-009-9192-9 19340611
77. Participation of gene expression in the protection against amyloid beta-peptide toxicity by the beta-amyloid precursor protein. Barger SW, Mattson MP, Ann N Y Acad Sci 1996 777 303 309 10.1111/j.1749-6632.1996.tb34437.x 8624104 (Pubitemid 26149206)
78. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM, Neuron 2008 58 42 51 10.1016/j.neuron.2008.02.003 18400162 (Pubitemid 351467029)
79. A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein. Schöbel S, Neumann S, Hertweck M, Dislich B, Kuhn PH, Kremmer E, Seed B, Baumeister R, Haass C, Lichtenthaler SF, J Biol Chem 2008 283 14257 14268 10.1074/jbc.M801531200 18353773
80. Fleecy amyloid deposits in the internal layers of the human entorhinal cortex are comprised of N-terminal truncated fragments of Abeta. Thal DR, Sassin I, Schultz C, Haass C, Braak E, Braak H, J Neuropathol Exp Neurol 1999 58 210 216 10.1097/00005072-199902000-00010 10029103 (Pubitemid 29088944)
81. Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R, Biochemistry 2005 44 10810 10821 10.1021/bi0508237 16086583 (Pubitemid 41153641)
82. Molecular dynamics simulations to investigate the aggregation behaviors of the Abeta(17-42) oligomers. Zhao JH, Liu HL, Liu YF, Lin HY, Fang HW, Ho Y, Tsai WB, J Biomol Struct Dyn 2009 26 481 490 19108587
83. The involvement of lipid rafts in Alzheimer's disease. Cordy JM, Hooper NM, Turner AJ, Mol Membr Biol 2006 23 111 122 10.1080/09687860500496417 16611586
84. APP processing and synaptic function. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R, Neuron 2003 37 925 937 10.1016/S0896-6273(03)00124-7 12670422 (Pubitemid 36398299)
85. Intraneuronal amyloid-beta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. Pierrot N, Ghisdal P, Caumont AS, Octave JN, J Neurochem 2004 88 1140 1150 10.1046/j.1471-4159. 2003.02227.x 15009669 (Pubitemid 38280681)
86. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, Xu H, Zhang YW, J Biol Chem 2007 282 10873 10880 10.1074/jbc.M608856200 17303576 (Pubitemid 47100783)
87. Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2. Cantara S, Donnini S, Morbidelli L, Giachetti A, Schulz R, Memo M, Ziche M, FASEB J 2004 18 1943 1945 15448110 (Pubitemid 39602292)
88. Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. Yan Y, Wang C, J Mol Biol 2006 364 853 862 10.1016/j.jmb.2006.09.046 17046788 (Pubitemid 44765041)
89. The Alzheimer's peptides Abeta40 and 42 adopt distinct conformations in water: a combined MD/NMR study. Sgourakis NG, Yan Y, McCallum SA, Wang C, Garcia AE, J Mol Biol 2007 368 1448 1457 10.1016/j.jmb.2007.02.093 17397862 (Pubitemid 46617600)
90. Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, Kim M, Sawamura N, Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, Michikawa M, J Neurochem 2003 87 609 619 10.1046/j.1471-4159.2003.02018.x 14535944 (Pubitemid 37310627)
91. A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, Michikawa M, Yanagisawa K, J Biol Chem 2007 282 2646 2655 17135262 (Pubitemid 47076773)
92. Effects of the monomeric, oligomeric, and fibrillar Abeta42 peptides on the proliferation and differentiation of adult neural stem cells from subventricular zone. Heo C, Chang KA, Choi HS, Kim HS, Kim S, Liew H, Kim JA, Yu E, Ma J, Suh YH, J Neurochem 2007 102 493 500 10.1111/j.1471-4159.2007.04499.x 17403034 (Pubitemid 47000592)
93. A novel action of alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. Michikawa M, Gong JS, Fan QW, Sawamura N, Yanagisawa K, J Neurosci 2001 21 7226 7235 11549733 (Pubitemid 32846970)
94. Inhibition of LTP in vivo by beta-amyloid peptide in different conformational states. Schmid AW, Freir DB, Herron CE, Brain Res 2008 1197 135 142 18237717
95. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. Wang HY, Lee DH, Davis CB, Shank RP, J Neurochem 2000 75 1155 1161 10936198 (Pubitemid 30660505)
96. The modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration. Alberghina L, Colangelo AM, BMC Neurosci 2006 7 Suppl 1 2 10.1186/1471-2202-7-S1-S2 17118156 (Pubitemid 351943981)
97. Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain. Simpson JE, Ince PG, Haynes LJ, Theaker R, Gelsthorpe C, Baxter L, Forster G, Lace GL, Shaw PJ, Matthews FE, Savva GM, Brayne C, Wharton SB, MRC Cognitive Function and Ageing Neuropathology Study Group, Neuropathol Appl Neurobiol 2010 36 25 40 10.1111/j.1365-2990.2009.01030.x 19422529
98. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, Savva G, Brayne C, Wharton SB, MRC Cognitive Function and Ageing Neuropathology Study Group, Neurobiol Aging 2010 31 578 590 10.1016/j.neurobiolaging.2008.05.015 18586353
99. Abeta(1-42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors. Abbott JJ, Howlett DR, Francis PT, Williams RJ, Neurobiol Aging 2008 29 992 1001 10.1016/j.neurobiolaging.2007.01.003 17292512 (Pubitemid 351697982)
100. {beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution. Gu Z, Liu W, Yan Z, J Biol Chem 2009 284 10639 10649 10.1074/jbc.M806508200 19240035
101. Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. Zhao D, Watson JB, Xie CW, J Neurophysiol 2004 92 2853 2858 10.1152/jn.00485.2004 15212428 (Pubitemid 40340496)
102. Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP(V717F) transgenic mice. Dodart JC, Bales KR, Johnstone EM, Little SP, Paul SM, Brain Res 2002 955 191 199 10.1016/S0006-8993(02)03437-6 12419536 (Pubitemid 35284849)
103. Clearance of amyloid beta-peptide from brain: transport or metabolism? Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B, Nat Med 2000 6 718 719 10888892 (Pubitemid 30469391)
104. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT, Ann Neurol 2000 47 739 747 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0. CO;2-8 10852539 (Pubitemid 30390194)
105. Interaction with amyloid beta peptide compromises the lipid binding function of apolipoprotein E. Tamamizu-Kato S, Cohen JK, Drake CB, Kosaraju MG, Drury J, Narayanaswami V, Biochemistry 2008 47 5225 5234 10.1021/bi702097s 18407659 (Pubitemid 351620759)
106. Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Furukawa K, Barger SW, Blalock EM, Mattson MP, Nature 1996 379 74 78 10.1038/379074a0 8538744 (Pubitemid 26008138)
107. CD74 interacts with APP and suppresses the production of Abeta. Matsuda S, Matsuda Y, D'Adamio L, Mol Neurodegener 2009 4 41 10.1186/1750-1326-4-41 19849849
108. Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor? Beel AJ, Mobley CK, Kim HJ, Tian F, Hadziselimovic A, Jap B, Prestegard JH, Sanders CR, Biochemistry 2008 47 9428 9446 10.1021/bi800993c 18702528
109. A novel reciprocal and biphasic relationship between membrane cholesterol and beta-secretase activity in SH-SY5Y cells and in human platelets. Liu WW, Todd S, Coulson DT, Irvine GB, Passmore AP, McGuinness B, McConville M, Craig D, Johnston JA, J Neurochem 2009 108 341 349 10.1111/j.1471-4159.2008.05753.x 19094065
110. Neuronal membrane cholesterol loss enhances amyloid peptide generation. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG, J Cell Biol 2004 167 953 960 10.1083/jcb.200404149 15583033 (Pubitemid 39628117)
111. Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. Avdulov NA, Chochina SV, Igbavboa U, Warden CS, Vassiliev AV, Wood WG, J Neurochem 1997 69 1746 1752 9326304 (Pubitemid 27406976)
112. Complex of amyloid beta peptides with 24-hydroxycholesterol and its effect on hemicholinium-3 sensitive carriers. Kristofiková Z, Kopeck V Jr, Hofbauerová K, Hovorková P, Rípová D, Neurochem Res 2008 33 412 421 10.1007/s11064-007-9443-5 17717740 (Pubitemid 351230441)
113. Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide. Shen Y, Sullivan T, Lee CM, Meri S, Shiosaki K, Lin CW, Brain Res 1998 796 187 197 10.1016/S0006-8993(98)00346-1 9689469 (Pubitemid 28343248)
114. Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. Mudher A, Chapman S, Richardson J, Asuni A, Gibb G, Pollard C, Killick R, Iqbal T, Raymond L, Varndell I, Sheppard P, Makoff A, Gower E, Soden PE, Lewis P, Murphy M, Golde TE, Rupniak HT, Anderton BH, Lovestone S, J Neurosci 2001 21 4987 4995 11438574 (Pubitemid 32622924)
115. Electrophysiological and cerebrovascular effects of the alpha-secretase-derived form of amyloid precursor protein in young and middle-aged rats. Sánchez-Alavez M, Chan SL, Mattson MP, Criado JR, Brain Res 2007 1131 112 117 17157827 (Pubitemid 46053899)
116. Alzheimer beta-amyloid blocks epileptiform activity in hippocampal neurons. Sepulveda FJ, Opazo C, Aguayo LG, Mol Cell Neurosci 2009 41 420 428 10.1016/j.mcn.2009.04.012 19427381
117. The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. Sabo SL, Ikin AF, Buxbaum JD, Greengard P, J Cell Biol 2001 153 1403 1414 10.1083/jcb.153.7.1403 11425871 (Pubitemid 34286125)
118. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. Kimberly WT, Zheng JB, Guénette SY, Selkoe DJ, J Biol Chem 2001 276 40288 40292 11544248
119. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. Ando K, Iijima KI, Elliott JI, Kirino Y, Suzuki T, J Biol Chem 2001 276 40353 40361 11517218
120. Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in beta-amyloid load. Santiard-Baron D, Langui D, Delehedde M, Delatour B, Schombert B, Touchet N, Tremp G, Paul MF, Blanchard V, Sergeant N, Delacourte A, Duyckaerts C, Pradier L, Mercken L, J Neurochem 2005 93 330 338 10.1111/j.1471-4159.2005.03026.x 15816856 (Pubitemid 40547490)
121. Phosphorylation of a tyrosine in the amyloid-beta protein precursor intracellular domain inhibits Fe65 binding and signaling. Zhou D, Zambrano N, Russo T, D'Adamio L, J Alzheimers Dis 2009 16 301 307 19221419
122. Furin is an endogenous regulator of alpha-secretase associated APP processing. Hwang EM, Kim SK, Sohn JH, Lee JY, Kim Y, Kim YS, Mook-Jung I, Biochem Biophys Res Commun 2006 349 654 659 10.1016/j.bbrc.2006.08.077 16942750 (Pubitemid 44344566)
123. Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. Mattson MP, Guo ZH, Geiger JD, J Neurochem 1999 73 532 537 10428048 (Pubitemid 29339825)
124. Secreted amyloid precursor protein alpha selectively suppresses N-methyl-D-aspartate currents in hippocampal neurons: involvement of cyclic GMP. Furukawa K, Mattson MP, Neuroscience 1998 83 429 438 9460751 (Pubitemid 28062633)
125. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Taylor CJ, Ireland DR, Ballagh I, Bourne K, Marechal NM, Turner PR, Bilkey DK, Tate WP, Abraham WC, Neurobiol Dis 2008 31 250 260 10.1016/j.nbd.2008.04.011 18585048
126. Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer's disease: an association with early beta-amyloid accumulation. Suo Z, Wu M, Citron BA, Wong GT, Festoff BW, J Neurosci 2004 24 3444 3452 10.1523/JNEUROSCI.4856-03.2004 15056724 (Pubitemid 38451910)
127. Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G(o). Nishimoto I, Okamoto T, Matsuura Y, Takahashi S, Okamoto T, Murayama Y, Ogata E, Nature 1993 362 75 79 10.1038/362075a0 8446172 (Pubitemid 23087295)
128. Ligand-dependent G protein coupling function of amyloid transmembrane precursor. Okamoto T, Takeda S, Murayama Y, Ogata E, Nishimoto I, J Biol Chem 1995 270 4205 4208 10.1074/jbc.270.9.4205 7876177
129. Interactions between the amyloid precursor protein C-terminal domain and G proteins mediate calcium dysregulation and amyloid beta toxicity in Alzheimer's disease. Shaked GM, Chauv S, Ubhi K, Hansen LA, Masliah E, FEBS J 2009 276 2736 2751 10.1111/j.1742-4658.2009.06997.x 19368557
130. Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Koudinov AR, Berezov TT, Kumar A, Koudinova NV, Clin Chim Acta 1998 270 75 84 10.1016/S0009-8981(97)00207-6 9544446 (Pubitemid 28095681)
131. Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases. Patey SJ, Edwards EA, Yates EA, Turnbull JE, J Med Chem 2006 49 6129 6132 10.1021/jm051221o 17004727 (Pubitemid 44484957)
132. Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics. Patey SJ, Edwards EA, Yates EA, Turnbull JE, Neurodegener Dis 2008 5 197 199 10.1159/000113701 18322389 (Pubitemid 351347849)
133. Interleukin-1beta enhances nucleotideinduced and alpha-secretase- dependent amyloid precursor protein processing in rat primary cortical neurons via up-regulation of the P2Y(2) receptor. Kong Q, Peterson TS, Baker O, Stanley E, Camden J, Seye CI, Erb L, Simonyi A, Wood WG, Sun GY, Weisman GA, J Neurochem 2009 109 1300 1310 10.1111/j.1471-4159.2009.06048.x 19317852
134. Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in
135. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WS, Neurobiol Aging 1996 17 761 766 10.1016/0197-4580(96)00104-2 8892349 (Pubitemid 26348877)
136. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Pérez A, Morelli L, Cresto JC, Castão EM, Neurochem Res 2000 25 247 255 10.1023/A:1007527721160 10786709 (Pubitemid 30210091)
137. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Young-Pearse TL, Chen AC, Chang R, Marquez C, Selkoe DJ, Neural Dev 2008 3 15 10.1186/1749-8104-3-15 18573216
138. Focal adhesions regulate Abeta signaling and cell death in Alzheimer's disease. Caltagarone J, Jing Z, Bowser R, Biochim Biophys Acta 2007 1772 438 445 17215111 (Pubitemid 46400386)
139. Alpha v integrins mediate beta-amyloid induced inhibition of long-term potentiation. Wang Q, Klyubin I, Wright S, Griswold-Prenner I, Rowan MJ, Anwyl R, Neurobiol Aging 2008 29 1485 1493 10.1016/j.neurobiolaging.2007.03.018 17442458
140. Interaction of Alzheimer beta-amyloid peptide(1-40) with lipid membranes. Terzi E, Holzemann G, Seelig J, Biochemistry 1997 36 14845 14852 10.1021/bi971843e 9398206 (Pubitemid 27524407)
141. Inhibition of the electrostatic interaction between beta-amyloid peptide and membranes prevents beta-amyloid-induced toxicity. Hertel C, Terzi E, Hauser N, Jakob-Rotne R, Seelig J, Kemp JA, Proc Natl Acad Sci USA 1997 94 9412 9416 10.1073/pnas.94.17.9412 9256496 (Pubitemid 27357843)
142. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. Verdier Y, Zarandi M, Penke B, J Pept Sci 2004 10 229 248 10.1002/psc.573 15160835 (Pubitemid 38594184)
143. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ, Proc Natl Acad Sci USA 2003 100 11735 11740 10.1073/pnas.1635130100 14504402 (Pubitemid 37206004)
144. Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. Saavedra L, Mohamed A, Ma V, Kar S, de Chaves EP, J Biol Chem 2007 282 35722 35732 10.1074/jbc.M701823200 17911110 (Pubitemid 350277136)
145. Modulation of amyloid precursor protein cleavage by cellular sphingolipids. Sawamura N, Ko M, Yu W, Zou K, Hanada K, Suzuki T, Gong JS, Yanagisawa K, Michikawa M, J Biol Chem 2004 279 11984 11991 10.1074/jbc. M309832200 14715666 (Pubitemid 38401704)
146. Alpha4beta2 nicotinic acetylcholine receptors are required for the amyloid beta protein-induced suppression of long-term potentiation in rat hippocampal CA1 region in vivo. Wu MN, He YX, Guo F, Qi JS, Brain Res Bull 2008 77 84 90 10.1016/j.brainresbull.2008.06.005 18602971
147. NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. Yamin G, J Neurosci Res 2009 87 1729 1736 10.1002/jnr.21998 19170166
148. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM, Neuron 2006 49 671 682 10.1016/j.neuron.2006.01.020 16504943 (Pubitemid 43290127)
149. M1 muscarinic agonists target major hallmarks of Alzheimer's disease-the pivotal role of brain M1 receptors. Fisher A, Neurodegener Dis 2008 5 237 240 10.1159/000113712 18322400 (Pubitemid 351347860)
150. Regulation of proteolytic processing of the amyloid beta-protein precursor of Alzheimer's disease in transfected cell lines and in brain slices. Nitsch RM, Slack BE, Farber SA, Schulz JG, Deng M, Kim C, Borghesani PR, Korver W, Wurtman RJ, Growdon JH, J Neural Transm Suppl 1994 44 21 27 7897393 (Pubitemid 24372885)
151. Regulated secretion of beta-amyloid precursor protein in rat brain. Farber SA, Nitsch RM, Schulz JG, Wurtman RJ, J Neurosci 1995 15 7442 7451 7472496 (Pubitemid 3010080)
152. Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. Liskowsky W, Schliebs R, Int J Dev Neurosci 2006 24 149 156 10.1016/j.ijdevneu.2005.11.010 16423497 (Pubitemid 43294621)
153. Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling. Zuchner T, Perez-Polo JR, Schliebs R, J Neurosci Res 2004 77 250 257 10.1002/jnr.20152 15211591 (Pubitemid 38859409)
154. Amyloid precursor protein processing is separately regulated by protein kinase C and tyrosine kinase in human astrocytes. Kim C, Jang CH, Bang JH, Jung MW, Joo I, Kim SU, Mook-Jung I, Neurosci Lett 2002 324 185 188 10.1016/S0304-3940(02)00217-3 12009519 (Pubitemid 34493865)
155. Cell-surface beta-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. Qiu WQ, Ferreira A, Miller C, Koo EH, Selkoe DJ, J Neurosci 1995 15 2157 2167 7891158
156. Transcriptional and translational regulation of BACE1 expression-implications for Alzheimer's disease. Rossner S, Sastre M, Bourne K, Lichtenthaler SF, Prog Neurobiol 2006 79 95 111 10.1016/j.pneurobio.2006.06.001 16904810 (Pubitemid 44247281)
157. Nuclear factor-kappaB activated by capacitative Ca2+ entry enhances muscarinic receptor-mediated soluble amyloid precursor protein (sAPPalpha) release in SH-SY5Y cells. Choi S, Kim JH, Roh EJ, Ko MJ, Jung JE, Kim HJ, J Biol Chem 2006 281 12722 12728 10.1074/jbc.M601018200 16490783 (Pubitemid 43855362)
158. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A, Brain Res 1998 792 331 334 10.1016/S0006-8993(98) 00138-3 9593977 (Pubitemid 28267549)
159. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY, Neuroscience 2002 110 199 211 10.1016/S0306-4522(01)00460-2 11958863 (Pubitemid 34214939)
160. Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. Dougherty JJ, Wu J, Nichols RA, J Neurosci 2003 23 6740 6747 12890766 (Pubitemid 36951200)
161. beta- Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB, J Biol Chem 2000 275 5626 5632 10.1074/jbc.275.8.5626 10681545 (Pubitemid 30115201)
162. Regulation of NMDA receptor trafficking by amyloid-beta. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P, Nat Neurosci 2005 8 1051 1058 10.1038/nn1503 16025111 (Pubitemid 41061516)
163. P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing. Camden JM, Schrader AM, Camden RE, González FA, Erb L, Seye CI, Weisman GA, J Biol Chem 2005 280 18696 18702 10.1074/jbc.M500219200 15778502 (Pubitemid 41379570)
164. The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling. Roncarati R, Sestan N, Scheinfeld MH, Berechid BE, Lopez PA, Meucci O, McGlade JC, Rakic P, D'Adamio L, Proc Natl Acad Sci USA 2002 99 7102 7107 10.1073/pnas.102192599 12011466 (Pubitemid 34526262)
165. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Etcheberrigaray R, Tan M, Dewachter I, Kuipéri C, Van der Auwera I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP, Van Leuven F, Alkon DL, Proc Natl Acad Sci USA 2004 101 11141 11146 10.1073/pnas.0403921101 15263077 (Pubitemid 38989597)
166. Protein kinase Calpha and beta1 isoforms are regulators of alpha-secretory proteolytic processing of amyloid precursor protein in vivo. Rossner S, Mendla K, Schliebs R, Bigl V, Eur J Neurosci 2001 13 1644 1648 10.1046/j.0953-816x.2001.01525.x 11328358 (Pubitemid 32423350)
167. Alzheimer's-specific effects of soluble beta-amyloid on protein kinase C-alpha and -gamma degradation in human fibroblasts. Favit A, Grimaldi M, Nelson TJ, Alkon DL, Proc Natl Acad Sci USA 1998 95 5562 5567 10.1073/pnas.95.10.5562 9576922 (Pubitemid 28224134)
168. Reelin signaling antagonizes beta-amyloid at the synapse. Durakoglugil MS, Chen Y, White CL, Kavalali ET, Herz J, Proc Natl Acad Sci USA 2009 106 15938 15943 10.1073/pnas.0908176106 19805234
169. The interactome of the amyloid beta precursor protein family members is shaped by phosphorylation of their intracellular domains. Tamayev R, Zhou D, D'Adamio L, Mol Neurodegener 2009 4 28 10.1186/1750-1326-4-28 19602287
170. Amyloid beta protein precursor is phosphorylated by JNK-1 independent of, yet facilitated by, JNK-interacting protein (JIP)-1. Scheinfeld MH, Ghersi E, Davies P, D'Adamio L, J Biol Chem 2003 278 42058 42063 10.1074/jbc.M304853200 12917434 (Pubitemid 37310471)
171. The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. Hoe HS, Cooper MJ, Burns MP, Lewis PA, van der Brug M, Chakraborty G, Cartagena CM, Pak DT, Cookson MR, Rebeck GW, J Neurosci 2007 27 10895 10905 10.1523/JNEUROSCI.3135-07.2007 17913923 (Pubitemid 47535874)
172. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. Stein TD, Johnson JA, J Neurosci 2002 22 7380 7388 12196559 (Pubitemid 35386337)
173. Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I, PLoS ONE 2008 3 2899 10.1371/journal.pone.0002899 18682830